Proposed MIC and disk diffusion microbiological cutoffs and spectrum of activity of retapamulin, a novel topical antimicrobial agent

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 11, 2008, Pages 3863-3867

  Traczewski, Maria M ^a   Brown, Steven D ^a  

^a CLINICAL MICROBIOLOGY INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLEUROMUTILIN; PSEUDOMONIC ACID; RETAPAMULIN;

ALPHA HEMOLYTIC STREPTOCOCCUS; ARTICLE; BACTERIUM ISOLATE; BETA HEMOLYTIC STREPTOCOCCUS; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED STUDY; CORRELATION ANALYSIS; DISK DIFFUSION; ENTEROCOCCUS; GRAM NEGATIVE BACTERIUM; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS, LOCAL; BICYCLO COMPOUNDS, HETEROCYCLIC; DISK DIFFUSION ANTIMICROBIAL TESTS; DRUG RESISTANCE, BACTERIAL; ENTEROCOCCUS; GRAM-NEGATIVE BACTERIA; HUMANS; MICROBIAL SENSITIVITY TESTS; MUPIROCIN; SKIN DISEASES, BACTERIAL; STAPHYLOCOCCAL SKIN INFECTIONS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS;

EID: 55849109644     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00399-08     Document Type: Article

References (24)

1. Clinical and Laboratory Standards Institute. 1999. Methods for determining bactericidal activity of antimicrobial agents; approved guideline. Document M26-A. CLSI, Wayne, PA.
2. Clinical and Laboratory Standards Institute. 2001. Development of in vitro susceptibility testing criteria and quality control parameters; approved guideline, 2nd ed. Document M23-A2. CLSI, Wayne, PA.
3. Clinical and Laboratory Standards Institute. 2007. Performance standard for antimicrobial susceptibility testing. Document M100-S17. CLSI, Wayne, PA.
4. Clinical and Laboratory Standards Institute. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 7th ed. Document M7-A7. CLSI, Wayne, PA.
5. Clinical and Laboratory Standards Institute. 2006. Performance standards for antimicrobial disk susceptibility tests; approved standard, 9th ed. Document M2-A9. CLSI, Wayne, PA.
6. Daum, R. S., S. Kar, and P. Kirkpatrick. 2007. Retapamulin. Nat. Rev. Drug Discov. 6:865-866.
7. Davidovich, C., A. Bashan, T. Auerbach-Nevo, R. D. Yaggie, R. R. Gontarek, and A. Yonath. 2007. Induced-fit tightens pleuromutilins binding to ribosomes and remote interactions enable their selectivity. Proc. Natl. Acad. Sci. USA 104:4291-4296.
8. European Medicines Agency. 2007 Altargo: summary of product characteristics. European Medicines Agency, London, United Kingdom. http://www.emea.europa.eu/humandocs/PDFs/EPAR/altargo/H-757-PI-en.pdf.
9. Reference deleted.
10. Food and Drug Administration. 2007. FDA labeling information Altabax (retapamulin). Food and Drug Administration, Washington, DC. http://www.fda.gov/cder/foi/label/2007/022055lbl.pdf.
11. Gentry, D. R., S. F. Rittenhouse, L. McCloskey, and D. J. Holmes. 2007. Stepwise exposure of Staphylococcus aureus to pleuromutilins is associated with stepwise acquisition of mutations in rplC and minimally affects susceptibility to retapamulin. Antimicrob. Agents Chemother. 51:2048-2052.
12. Goldstein, E. J. C., D. M. Citron, C. V. Merriam, Y. A. Warren, K. L. Tyrrell, and H. T. Fernandez. 2006. Comparative in vitro activities of retapamulin (SB-275833) against 141 clinical isolates of Propionibacterium spp., including 117 P. acnes isolates. Antimicrob. Agents Chemother. 50:379-381.
13. Hunt, E. 2000. Pleuromutilin antibiotics. Drugs Future 25:1163-1168.
14. Jones, R. N., T. R. Fritsche, H. S. Sader, and J. E. Ross. 2006. Activity of retapamulin (SB-275833), a novel pleuromutilin, against selected resistant gram-positive cocci. Antimicrob. Agents Chemother. 50:2583-2586.
15. Kavanagh, F., A. Hervey, and W. J. Robbins. 1951. Antibiotic substances from Basidiomycetes: VIII Pleurotus Mutilus (Fr.) Sacc. and Pleurotus Passeckerianus Pilat. Proc. Natl. Acad. Sci. USA 37:570-574.
16. Kosowska-Shick, K., C. Clark, K. Credito, P. McGhee, B. Dewasse, T. Bogdanovich, and P. C. Appelbaum. 2006. Single and multistep resistance selection studies on the activity of retapamulin compared to other agents against Staphylococcus aureus and Streptococcus pyogenes. Antimicrob. Agents Chemother. 50:765-769.
17. Long, K. S., J. Poehlsgaard, C. Kehrenberg, S. Schwarz, and B. Vester. 2006. The cfr rRNA methyltransferase confers resistance to phenicols, lincosamides, oxazolidinones, pleuromutilins, and streptogramin A antibiotics. Antimicrob. Agents Chemother. 50:2500-2505.
18. Mendes, R. E., L. Deshpande, M. Castanheira, J. DiPersio, M. Saubolle, and R. N. Jones. 7 April 2008. First report of cfr-mediated resistance to linezolid in human staphylococcal clinical isolates recovered in the United States. Antimicrob. Agents Chemother. doi:10.1128/AAC.00231-08.
19. Pankuch, G. A., G. Lin, D. B. Hoellman, C. E. Good, M. R. Jacobs, and P. C. Appelbaum. 2006. Activity of retapamulin against Streptococcus pyogenes and Staphylococcus aureus evaluated by agar dilution, microdilution, E-test, and disk diffusion methodologies. Antimicrob. Agents Chemother. 50:1727-1730.
20. Rittenhouse, S., S. Biswas, J. Broskey, L. McCloskey, T. Moore, S. Vasey, J. West, M. Zalacain, R. Zonis, and D. Payne. 2006. Selection of retapamulin, a novel pleuromutilin for topical use. Antimicrob. Agents Chemother. 50:3882-3885.
21. Ross, J. E., and R. N. Jones. 2005. Quality control guidelines for susceptibility testing of retapamulin (SB-275833) by reference and standardized methods. J. Clin. Microbiol. 43:6212-6213.
22. Toh, S. M., L. Xiong, C. A. Arias, M. V. Villegas, K. Lolans, J. Quinn, and A. S. Mankin. 2007. Acquisition of a natural resistance gene renders a clinical strain of methicillin-resistant Staphylococcus aureus resistant to the synthetic antibiotic linezolid. Mol. Microbiol. 64:1506-1514.
23. Turnidge, J., and D. L. Paterson. 2007. Setting and revising antibacterial susceptibility breakpoints. Clin. Microbiol. Rev. 20:391-408.
24. Yan, K., L. Madden, A. E. Choudhry, C. S. Voigt, R. A. Copeland, and R. R. Gontarek. 2006. Biochemical characterization of the interactions of the novel pleuromutilin derivative retapamulin with bacterial ribosomes. Antimicrob. Agents Chemother. 50:3875-3881.